Compound library/Primary-source evidence guide

Sermorelin

Growth-hormone secretagogue evidence, historical labeling, and limits of online anti-aging claims

Sermorelin is a synthetic growth hormone-releasing hormone fragment historically used in diagnostic or pediatric growth contexts. Current online use often shifts it into anti-aging, sleep, recovery, or body-composition claims that require a separate evidence and safety review.

Editorial status

This page aggregates regulatory documents and published human research. Its claims, citations, populations, and limitations received an independent editorial evidence check. Last editorial audit: .

It has not been medically reviewed by a clinician. It provides general education, not diagnosis, treatment, dosing instructions, or advice for an individual. Use the product-specific official information and consult a qualified clinician or pharmacist for personal decisions.

Product and regulatory distinctions

A compound name is not one interchangeable set of instructions. Product, formulation, indication, labeling, and jurisdiction matter.

Historical Geref products

FDA records state that Geref NDAs were approved for pediatric idiopathic growth-hormone deficiency with growth failure and for pituitary GH-secretory evaluation, then withdrawn after discontinuation; FDA determined the withdrawals were not for safety or effectiveness reasons.

Current source

Compounded or online sermorelin

Compounded products are not FDA-approved and do not undergo FDA premarket review for safety, effectiveness, or quality.

Current source

Sport context

Growth-hormone related releasing factors may raise anti-doping issues for covered athletes.

Current source

Claim-by-claim evidence map

Each finding is tied to the population and product actually studied. Trial results are not personal predictions.

Observational human evidence

GHRH(1-29)-NH2 produced a transient growth-hormone response in a human pharmacology study.

Population
30 healthy men aged 19 to 43.
Finding
Intravenous administration produced measurable GH release; the study characterized pharmacokinetics and hormone response.
Limits
It did not test anti-aging, sleep, recovery, longevity, or body-composition outcomes, and intranasal bioavailability was low in the tested formulation.
Pharmacokinetics of growth hormone-releasing hormone(1-29)-NH2 and stimulation of growth hormone secretion in healthy subjects after intravenous or intranasal administration
Unsupported or anecdotal

Historical U.S. approvals were limited to pediatric growth failure and pituitary diagnostic testing.

Population
The labeled populations in the historical Geref NDAs.
Finding
FDA's withdrawal notice identifies those historical indications and states that the products were discontinued and the approvals withdrawn.
Limits
Historical indications do not establish efficacy for contemporary wellness use or authenticate a compounded product.
Determination That Geref products were not withdrawn for reasons of safety or effectiveness
Unsupported or anecdotal

Historical product evidence does not establish the quality of a compounded or online sermorelin product.

Population
People considering currently compounded or online products.
Finding
FDA does not review compounded drugs before marketing for safety, effectiveness, or quality.
Limits
This does not prove that a specific vial is defective; it explains why product-specific quality cannot be inferred from the molecule name.
Compounded Drugs: Questions and Answers

What this evidence does not answer

  • No adequate evidence base establishes sermorelin as a general anti-aging intervention.
  • Long-term endocrine effects of nonindicated use require medical oversight.
  • Marketing claims rarely disclose comparator, endpoint, discontinuation, or adverse-event data.

Useful information to organize between visits

  • Exact product and source
  • Baseline diagnosis or reason for endocrine evaluation
  • Concurrent hormones, medicines, and labs
  • Symptoms and clinical follow-up

Questions to bring to a clinician or pharmacist

  1. 1.Is there a diagnosed indication for endocrine testing or treatment?
  2. 2.What monitoring would be needed before and during use?
  3. 3.What risks apply with my pituitary, glucose, cancer, or sleep history?

Primary sources

  1. Pharmacokinetics of growth hormone-releasing hormone(1-29)-NH2 and stimulation of growth hormone secretion in healthy subjects after intravenous or intranasal administrationActa Paediatrica Supplement · Published 1993-03 · Accessed July 12, 2026
  2. Determination That Geref products were not withdrawn for reasons of safety or effectivenessU.S. Food and Drug Administration / Federal Register · Published March 4, 2013 · Accessed July 12, 2026
  3. Compounded Drugs: Questions and AnswersU.S. Food and Drug Administration · Published Current guidance · Accessed July 12, 2026
  4. 2026 Prohibited ListWorld Anti-Doping Agency · Published 2026 · Accessed July 12, 2026

Turn scattered notes into a useful treatment history

Dosi organizes timing, locations, symptoms, reminders, and questions for your next appointment. It does not prescribe or replace your care team.

Start tracking free